EWTX
Edgewise Therapeutics, Inc. NASDAQ Listed Mar 26, 2021$35.58
Mkt Cap $3.8B
52w Low $12.15
84.3% of range
52w High $39.96
50d MA $31.38
200d MA $22.92
P/E (TTM)
-18.8x
EV/EBITDA
-15.1x
P/B
6.0x
Debt/Equity
0.0x
ROE
-32.1%
P/FCF
-17.8x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$31.38
200d MA
$22.92
Avg Volume
900.8K
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
3415 Colorado Avenue · Boulder, CO 80303 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 36.99 | +2.7% | -3.8% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.43 | -0.47 | -9.3% | 29.66 | -0.4% | +2.6% | +0.1% | -2.9% | -2.6% | -4.3% | — |
| Nov 6, 2025 | AMC | -0.40 | -0.39 | +2.5% | 17.09 | -0.2% | +0.4% | +7.0% | +25.7% | +23.9% | +19.5% | — |
| Aug 7, 2025 | AMC | -0.42 | -0.34 | +19.0% | 12.95 | +0.3% | -2.1% | +0.3% | +3.4% | +6.0% | +7.6% | — |
| May 8, 2025 | AMC | -0.45 | -0.43 | +4.4% | 14.70 | +1.7% | -0.8% | +0.8% | +1.3% | -1.0% | -1.7% | — |
| Mar 3, 2025 | AMC | -0.39 | -0.42 | -7.7% | 25.53 | -1.6% | -4.0% | +4.6% | +10.2% | +9.7% | +7.8% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.36 | +2.7% | 35.43 | -1.3% | +2.7% | -0.3% | -0.6% | -6.1% | -7.2% | — |
| Aug 8, 2024 | AMC | -0.36 | -0.34 | +5.6% | 16.19 | +0.2% | +1.6% | +5.3% | +5.6% | +5.3% | +16.6% | — |
| May 9, 2024 | AMC | -0.39 | -0.33 | +15.4% | 20.00 | -4.5% | -8.3% | -12.6% | -12.8% | -11.6% | -9.1% | — |
| Feb 22, 2024 | AMC | -0.44 | -0.47 | -6.8% | 17.37 | +5.8% | -0.5% | -1.9% | -3.0% | -4.1% | -6.0% | — |
| Nov 9, 2023 | AMC | -0.40 | -0.41 | -2.5% | 5.72 | -0.3% | -3.7% | +7.2% | +13.8% | +14.7% | +11.0% | — |
| Aug 10, 2023 | AMC | -0.41 | -0.34 | +17.1% | 6.74 | +0.0% | -0.4% | +0.4% | +8.3% | +7.3% | +5.0% | — |
| May 11, 2023 | AMC | -0.37 | -0.36 | +2.7% | 9.52 | -0.8% | -2.6% | -5.2% | -1.6% | -2.4% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $29.78 | $30.41 | +2.1% | +2.4% | -0.3% | +0.9% | -2.4% | +0.1% |
| Mar 17 | JP Morgan | Maintains | Overweight → Overweight | — | $29.78 | $30.41 | +2.1% | +2.4% | -0.3% | +0.9% | -2.4% | +0.1% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $29.66 | $29.55 | -0.4% | +2.6% | +0.1% | -2.9% | -2.6% | -4.3% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $20.42 | $20.52 | +0.5% | +11.4% | +9.0% | +8.5% | +9.4% | +9.0% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $17.09 | $17.05 | -0.2% | +0.4% | +7.0% | +25.7% | +23.9% | +19.5% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $17.09 | $17.05 | -0.2% | +0.4% | +7.0% | +25.7% | +23.9% | +19.5% |
| Aug 19 | JP Morgan | Maintains | Overweight → Overweight | — | $14.00 | $14.02 | +0.1% | -1.4% | -1.1% | +4.4% | +6.1% | +2.1% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $12.95 | $12.99 | +0.3% | -2.1% | +0.3% | +3.4% | +6.0% | +7.6% |
| Jun 5 | RBC Capital | Maintains | Outperform → Outperform | — | $14.49 | $14.47 | -0.1% | +2.3% | +5.2% | +5.3% | +6.6% | +8.7% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $14.45 | $14.48 | +0.2% | +2.3% | +2.4% | +2.9% | +1.0% | -3.0% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $14.70 | $14.95 | +1.7% | -0.8% | +0.8% | +1.3% | -1.0% | -1.7% |
| Apr 21 | Wedbush | Maintains | Outperform → Outperform | — | $13.45 | $13.36 | -0.7% | -1.1% | +0.6% | +10.3% | +14.5% | +10.3% |
| Apr 3 | RBC Capital | Maintains | Outperform → Outperform | — | $15.52 | $14.90 | -4.0% | -12.5% | -25.8% | -23.8% | -26.0% | -19.5% |
| Apr 3 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $15.52 | $14.90 | -4.0% | -12.5% | -25.8% | -23.8% | -26.0% | -19.5% |
| Apr 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.13 | $14.50 | -28.0% | -22.9% | -32.5% | -42.8% | -41.2% | -42.9% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $25.53 | $25.12 | -1.6% | -4.0% | +4.6% | +10.2% | +9.7% | +7.8% |
| Dec 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.69 | $33.37 | +2.1% | -7.7% | -8.2% | -5.8% | -5.8% | -8.3% |
| Nov 27 | Truist | Maintains | Buy → Buy | — | $32.08 | $33.16 | +3.4% | +0.4% | +2.9% | -1.7% | -0.4% | -0.1% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $35.43 | $34.96 | -1.3% | +2.7% | -0.3% | -0.6% | -6.1% | -7.2% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.99 | $29.99 | +0.0% | +6.4% | +6.1% | +10.0% | +16.8% | +18.4% |
| Sep 20 | RBC Capital | Maintains | Outperform → Outperform | — | $29.50 | $29.94 | +1.5% | -4.1% | -10.2% | -12.1% | -12.3% | -11.9% |
| Sep 19 | Truist | Maintains | Buy → Buy | — | $19.07 | $25.75 | +35.0% | +54.7% | +48.3% | +38.9% | +35.9% | +35.7% |
| Sep 17 | RBC Capital | Maintains | Outperform → Outperform | — | $16.86 | $17.11 | +1.5% | +7.2% | +13.1% | +75.0% | +67.7% | +57.1% |
| Aug 16 | Wedbush | Maintains | Outperform → Outperform | — | $18.87 | $18.88 | +0.1% | -2.2% | -0.3% | +4.5% | +11.0% | +3.8% |
| Aug 12 | JP Morgan | Maintains | Overweight → Overweight | — | $16.45 | $16.50 | +0.3% | +3.6% | +3.9% | +3.6% | +14.7% | +12.2% |
| Jul 25 | RBC Capital | Maintains | Outperform → Outperform | — | $21.18 | $21.29 | +0.5% | -11.6% | -10.4% | -14.9% | -19.5% | -19.6% |
| Jul 10 | RBC Capital | Maintains | Outperform → Outperform | — | $22.85 | $22.92 | +0.3% | -5.8% | -2.3% | -1.9% | +0.1% | -2.8% |
| Jul 9 | JP Morgan | Maintains | Overweight → Overweight | — | $20.92 | $21.00 | +0.4% | +9.2% | +2.9% | +6.7% | +7.2% | +9.3% |
| Jul 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.01 | $17.99 | -0.1% | +7.6% | +2.1% | +1.5% | +7.9% | +16.2% |
| Jun 26 | Wedbush | Maintains | Outperform → Outperform | — | $17.39 | $17.77 | +2.2% | +0.5% | +0.6% | +3.6% | +11.4% | +5.7% |
| Apr 22 | RBC Capital | Maintains | Outperform → Outperform | — | $15.23 | $15.93 | +4.6% | -1.0% | +2.8% | +5.8% | +4.7% | +6.2% |
| Apr 17 | Truist | Maintains | Buy → Buy | — | $16.63 | $16.85 | +1.3% | -5.9% | -7.1% | -8.4% | -9.3% | -5.9% |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $16.48 | $16.28 | -1.2% | +0.9% | -5.0% | -6.2% | -7.6% | -8.5% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $16.75 | $16.73 | -0.1% | +5.8% | +3.9% | +1.9% | +1.0% | -7.3% |
| Nov 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.72 | $5.70 | -0.3% | -3.7% | +7.2% | +13.8% | +14.7% | +11.0% |
| Aug 16 | Wedbush | Maintains | Outperform → Outperform | — | $7.30 | $7.24 | -0.8% | -1.0% | -3.0% | -1.5% | -0.4% | +0.1% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $6.74 | $6.74 | +0.0% | -0.4% | +0.4% | +8.3% | +7.3% | +5.0% |
| Jun 30 | JP Morgan | Maintains | Overweight → Overweight | — | $7.53 | $7.98 | +6.0% | +2.9% | +0.1% | +1.7% | -1.3% | -3.2% |
| Jun 28 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.95 | +5.9% | +0.7% | +0.3% | +3.2% | +0.4% | +2.0% |
| Jun 28 | Truist | Maintains | Buy → Buy | — | $7.51 | $7.95 | +5.9% | +0.7% | +0.3% | +3.2% | +0.4% | +2.0% |
| Jun 27 | Truist | Maintains | Buy → Buy | — | $6.86 | $6.88 | +0.3% | +9.5% | +10.2% | +9.8% | +13.0% | +9.9% |
| Jun 20 | JP Morgan | Maintains | Overweight → Overweight | — | $8.30 | $7.96 | -4.1% | -1.3% | -4.0% | -5.7% | -8.4% | -17.3% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $9.02 | $8.86 | -1.8% | +3.8% | +3.0% | +3.2% | +1.7% | +7.4% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $9.52 | $9.44 | -0.8% | -2.6% | -5.2% | -1.6% | -2.4% | -2.2% |
| Feb 28 | JP Morgan | Maintains | Overweight → Overweight | — | $9.44 | $9.43 | -0.1% | +1.5% | +1.6% | -0.8% | -0.1% | -6.8% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $10.04 | $10.27 | +2.3% | -4.7% | -4.5% | -4.4% | -6.4% | +4.5% |
| Aug 25 | Goldman Sachs | Downgrade | Neutral → Sell | — | $11.02 | $9.52 | -13.6% | -7.4% | -11.0% | -8.6% | -9.4% | -8.5% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.27 | $7.13 | -1.9% | -12.7% | -22.0% | -20.8% | -16.5% | -14.0% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.07 | $6.94 | -1.8% | +5.7% | +10.7% | +3.1% | +4.4% | +2.7% |
| May 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.07 | $6.94 | -1.8% | +5.7% | +10.7% | +3.1% | +4.4% | +2.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Donovan Joanne M. | CMO | Sell | 50,000 | $38.57 | $1.9M | 4,367 | -2.68% | — |
| May 4, 2026 | Donovan Joanne M. | CMO | Sell | 5,230 | $31.29 | $164K | 4,367 | -2.68% | — |
8-K · 2.02
!! High
Edgewise Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Edgewise Therapeutics (EWTX) released Q1 2026 financial results, providing investors with updates on its operational performance and financial condition for the quarter ending March 31, 2026.
May 7
8-K
Edgewise Therapeutics, Inc. -- 8-K Filing
Edgewise Therapeutics reported strong 2025 financial results and execution, positioning the company for transformative growth in the upcoming year.
Feb 26
Data updated apr 25, 2026 8:07am
· Source: massive.com